Form 8-K - Current report:
SEC Accession No. 0001819790-25-000100
Filing Date
2025-06-18
Accepted
2025-06-18 16:05:46
Documents
12
Period of Report
2025-06-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K tars-20250612.htm   iXBRL 8-K 42690
  Complete submission text file 0001819790-25-000100.txt   158823

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20250612.xsd EX-101.SCH 1773
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20250612_lab.xml EX-101.LAB 21629
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20250612_pre.xml EX-101.PRE 12502
14 EXTRACTED XBRL INSTANCE DOCUMENT tars-20250612_htm.xml XML 2833
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 251056881
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)